Journal of Hepatology
IF
25.08
Papers
38k
Papers 10,000
1 page of 1,000 pages (10k results)
Newest
#1M. Reig (UB: University of Barcelona)H-Index: 6
#2Alejandro Forner (UB: University of Barcelona)H-Index: 34
Last. Jordi Bruix (UB: University of Barcelona)H-Index: 117
view all 16 authors...
Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into ...
Source
#1Mazen NoureddinH-Index: 27
#2Emily Truong (Cedars-Sinai Medical Center)
Last. Naim AlkhouriH-Index: 48
view all 10 authors...
Abstract null null Background and Aims null A priority is identification of patients with fibrotic nonalcoholic steatohepatitis (Fibro-NASH) defined as NASH with nonalcoholic fatty liver disease activity score ≥ 4 and significant fibrosis (≥ F2). These patients are at highest risk for disease progression and will benefit most from pharmacologic treatment. MRI-based proton density fat fraction (MRI-PDFF) and MR elastography (MRE) risk-stratifies NAFLD patients by assessing steatosis and fibrosis,...
Source
#1Victoria T. Kronsten (KCL: King's College London)H-Index: 2
#2Thomas H. Tranah (KCL: King's College London)H-Index: 7
Last. Debbie L. Shawcross (KCL: King's College London)H-Index: 41
view all 4 authors...
Abstract: null null Depression and chronic liver disease (CLD) are important causes of disability, morbidity and mortality worldwide and their prevalence continues to rise. The rate of depression in CLD is high compared to that of the general population and is comparable to the increased rates observed in other medical comorbidities and chronic inflammatory conditions. Notably, a comorbid diagnosis of depression has a detrimental effect on outcomes in cirrhosis. null Systemic inflammation is piv...
Source
#1Yuchen Liu (Harvard University)H-Index: 4
#2Shu Zhuo (Harvard University)
Last. Yingzi Yang (Harvard University)H-Index: 42
view all 9 authors...
Background & aims null Primary liver tumors contain distinct subtypes. A subset of iCCAs can arise from cell fate reprogramming of mature hepatocytes in mouse models. However, the underpinning of cell fate plasticity during hepatocarcinogenesis is still poorly understood, hampering therapeutic development to treat HCC and iCCA. As YAP activation induces liver tumor formation and cell fate plasticity, we investigated the role of Sox9, a transcription factor downstream of Yap activation and expres...
Source
#1Guang-Yu Ding (Fudan University)H-Index: 8
#2Jiaqiang Ma (Fudan University)H-Index: 6
Last. Qiang GaoH-Index: 14
view all 20 authors...
Background & aims null To investigate the prognostic value and relevant mechanisms of tertiary lymphoid structures (TLSs) in intrahepatic cholangiocarcinoma (iCCA). null Methods null We retrospectively included 962 patients from three cancer centers across China. The TLSs at different anatomic subregions were quantified and correlated with overall survival (OS) by Cox regression and Kaplan-Meier analyses. Multiplex immunohistochemistry (mIHC) was applied to characterize the composition of TLSs i...
Source
#1Mary E. Rinella (NU: Northwestern University)H-Index: 40
#2Jean-François Dufour (UB: University of Bern)H-Index: 64
Last. Vlad Ratziu (University of Paris)H-Index: 64
view all 15 authors...
Abstract null null Background & Aims null Nonalcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver disease that can lead to cirrhosis. While liver biopsy is considered the reference standard for histologic diagnosis of NASH and staging of fibrosis, use in clinical practice is limited. Noninvasive tests (NITs) are increasingly being used to identify and stage liver fibrosis in patients with NASH, and several can assess liver-related outcomes. We report changes in various NITs ...
Source
#1Eleonora Scorletti (University of Pennsylvania)H-Index: 19
#2Rotonya M. Carr (UW: University of Washington)
Lipid droplets (LDs) are complex and metabolically active organelles. They are composed of a neutral lipid core surrounded by a monolayer of phospholipids and proteins. LD accumulation in hepatocytes is the distinctive characteristic of non-alcoholic fatty liver disease (NAFLD). NAFLD is a chronic, heterogeneous liver condition that can progress to liver fibrosis and hepatocellular carcinoma. Though recent research has improved our understanding of the mechanisms linking LDs accumulation to NAFL...
Source
#1Delia D'Avola (University of Navarra)H-Index: 20
#2Alessandro Granito (UNIBO: University of Bologna)H-Index: 47
Last. Fabio Piscaglia (UNIBO: University of Bologna)H-Index: 80
view all 4 authors...
Any oncological treatment must aim at maximizing patient survival with the best quality of life and not merely at eliminating the tumor. Since the liver has a vital function, any radical treatment severely compromising liver function will result in a shortening of life expectancy, rather than a prolongation. Furthermore, even non-severe liver damage may imply the risk of impeding the opportunity to receive further effective therapies. This is particularly important in the case of hepatocellular ...
Source
#1Krishnakant Saboo (UIUC: University of Illinois Urbana-Champaign)H-Index: 5
#2Nikita Petrakov (UIUC: University of Illinois Urbana-Champaign)
Last. Jasmohan S. Bajaj (VCU: Virginia Commonwealth University)H-Index: 72
view all 10 authors...
Abstract null null Background and Aims null Salivary and stool microbiota are altered in cirrhosis. Since stool is logistically difficult to collect compared to saliva, it is important to determine their relative capability in differentiating groups. We aimed to determine the ability of stool versus salivary microbiota in differentiating between groups using machine learning (ML). null null null Methods null Controls and outpatients with cirrhosis underwent saliva and stool microbiome analysis. ...
Source
#1Xinxing Tantai (XJTU: Xi'an Jiaotong University)H-Index: 3
#2Yi Liu (XJTU: Xi'an Jiaotong University)
Last. Mindie H. Nguyen (SU: Stanford University)H-Index: 49
view all 32 authors...
Abstract null null Background & Aims null The association between sarcopenia and prognosis in patients with cirrhosis remains to be determined. In this study, we aimed to quantify the association between sarcopenia and the risk of mortality in patients with cirrhosis, by sex, underlying liver disease etiology, and severity of hepatic dysfunction. null null null Methods null PubMed, Web of Science, EMBASE, and major scientific conference sessions were searched without language restriction through...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.